Amorphical

Crohn's disease
#Amorphical #Crohn's disease #Inflammatory Bowel Disease #Phase II trial

Novel non-immunosuppressive approach for Crohn’s

Amorphical has announced positive final long-term follow-up data from its Phase II clinical trial evaluating its investigational nano-amorphous Calcium Carbonate (ACC) therapy, for the treatment of moderate-to-severe Crohn’s disease.  The full data analysis, including a cohort of patients who completed follow-up extending up to 48 weeks post-baseline,… Read More

#News